Contura Vet Limited, a wholly owned subsidiary of Contura Animal Health Holdings Limited, (“Contura Vet”), the owner and distributor of ArthramidVet®, an innovative veterinary medical product used for the treatment of lameness in horses and companion animals, is pleased to announce the acquisition of Innovative Medical Solutions Limited (“IMS Vet”).
Contura Vet is also pleased to announce the appointment of Dr Jason Lowe as Chief Veterinary Officer, reporting to Rakesh Tailor, Chief Executive Officer.
Contura Vet is known for its unique hydrogel products for animals. ArthramidVet® is licenced for the treatment of equine osteoarthritis in Australia, New Zealand and United Arab Emirates, and is approved for sale in the US. Use of the same hydrogel technology is being expanded into companion animals for osteoarthritis.
The companies will combine existing infrastructure, knowledge and expertise in the field of veterinary orthopaedics to provide the best in innovation, manufacturing, distribution, clinical education and product support.
Commenting on the transaction, Rakesh Tailor, Chief Executive Officer of Contura said:
“We are delighted to have acquired IMS and expand our direct commercial footprint to Australia and New Zealand, important markets in the equine field. I am especially excited to have Dr Jason Lowe as our Chief Veterinary Officer as his expertise and experience in equine medicine will be an invaluable addition to the leadership of our team. Jason will oversee the commercial business in the Asia Pacific region for Contura Vet which is all part of our plan to make ArthramidVet®, already one of the fastest growing treatments for osteoarthritis in horses, available and accessible to more patients around the world.”
Dr Jason Lowe, Chief Executive Officer of IMS, commented:
“Joining forces with Contura Animal Health is a natural progression for IMS Vet. Our shared vision for excellence in veterinary care and commitment to innovation in hydrogel technology will drive our collective mission forward. I am confident that together, we will continue to make significant strides in advancing veterinary medicine and improving the lives of animals. Ambitions are bold and I look forward to being an intrinsic part of the story.”
Further information:
About Contura
Contura is headquartered in London and has its manufacturing facility in Copenhagen, Denmark. It develops and manufactures innovative medical products in the fields of soft tissue augmentation, orthopaedics and animal health using its unique, patented hydrogel technology. Its hydrogel based products are non-particulate and do not contain a carrier gel, allowing for its non-absorbable, non-migratory and highly durable properties. For more information, visit www.contura.com.
About IMS
Innovative Medical Solutions Limited (IMS Vet), led by Dr. Jason Lowe, specialises in advanced veterinary services and the unique 2.5% injectable polyacrylamide ArthramidVet®. With a strong emphasis on innovation and research, IMS Vet has established itself as a trusted name in the veterinary community, particularly in the field of equine joint health.
As part of Contura Animal Health, IMS Vet will benefit from expanded resources, research capabilities, and global reach. Clients can expect continued access to high-quality veterinary products and services, supported by Contura Animal Health’s robust infrastructure and expertise.
The acquisition is expected to be seamless, with no disruption to existing services. Clients and partners of IMS Vet will continue to receive the same level of exceptional care and support they have come to trust.
About Arthrosamid®
Arthrosamid® is a 2.5% polyacrylamide hydrogel developed by Contura as a long-lasting intra-articular injection approved in Europe for the symptomatic treatment of human patients with knee osteoarthritis. Development of Arthrosamid® commenced after the generation of impressive clinical data with ArthramidVet®, a related product of the company, in the treatment of lameness in horses. Arthrosamid® becomes embedded in the synovial membrane, providing support and structure and other therapeutic benefits to patients with knee osteoarthritis. Patients benefit from both pain relief and improved mobility. For more information, visit www.arthrosamid.com.
About ArthramidVet®
ArthramidVet® is a biocompatible 2.5% polyacrylamide hydrogel for intra-articular injection in horses and companion animals. Upon injection into the joint, ArthramidVet® adheres to the synovial lining through its ability to exchange water molecules. It increases the tensile strength of the joint capsule, improving lameness. ArthramidVet® has demonstrated an 82.5% successful resolution of joint lameness out to 24 months in horses. For more information, visit https://conturavet.com/.
